Drug · CHEMBL477
ADENOSINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ADENOSINE. Drugs and targets, record CHEMBL477. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL477
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 23 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADORA1 | Adenosine receptor | Adenosine receptor agonist | AGONIST | https://conductscience.org/library/genes/134 |
| ADORA2A | Adenosine receptor | Adenosine receptor agonist | AGONIST | https://conductscience.org/library/genes/135 |
| ADORA2B | Adenosine receptor | Adenosine receptor agonist | AGONIST | https://conductscience.org/library/genes/136 |
| ADORA3 | Adenosine receptor | Adenosine receptor agonist | AGONIST | https://conductscience.org/library/genes/140 |
Source ChEMBL
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| myocardial infarction | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
| Supraventricular tachycardia | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=HP_0004755 |
| atrial fibrillation | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0004981 |
| Paroxysmal supraventricular tachycardia | Approval | TTD | 2 | 1 | https://conductscience.org/library/drugs?q=HP_0004763 |
| B-cell chronic lymphocytic leukemia | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004948 |
| His bundle tachycardia | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0017989 |
| Paroxysmal atrial fibrillation | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0004757 |
| Tachycardia | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0001649 |
| Tako-tsubo cardiomyopathy | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0019018 |
| acute respiratory distress syndrome | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006502 |
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials76
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 8 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01932112 | Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial) | Phase 3 | 378 | 2016-04-13 | adenosine | Its name | ClinicalTrials.gov |
| NCT03557385 | Adenosine Contrast CorrELations in Evaluating RevAscularizaTION | Phase 4 | 201 | 2024-04-02 | adenosine | Its name | ClinicalTrials.gov |
| NCT03032965 | Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation | Phase 2 | 131 | 2017-12-13 | adenosine | Its name | ClinicalTrials.gov |
| NCT01482169 | Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR) | 48 | 2018-05-11 | adenosine | Its name | ClinicalTrials.gov | |
| NCT01234870 | Comprehensive Evaluation of Ischemic Heart Disease Using MRI | Phase 2/3 | 40 | 2014-09-26 | adenosine | Its name | ClinicalTrials.gov |
| NCT03249272 | Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Phase 4 | 31 | 2020-09-16 | adenosine | Its name | ClinicalTrials.gov |
| NCT00859833 | Effects of Body Mass Index on the Hyperemic Response to Regadenoson | 30 | 2011-05-24 | adenosine | Its name | ClinicalTrials.gov | |
| NCT04392362 | A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT) | Phase 3 | 30 | 2021-06-25 | adenosine | Its name | ClinicalTrials.gov |
| NCT00349921 | Clonidine Versus Adenosine to Treat Neuropathic Pain | Phase 2 | 24 | 2014-02-26 | adenosine | Its name | ClinicalTrials.gov |
| NCT01495481 | Dexmedetomidine and Adenosine: Therapeutic Use for SVT | 22 | 2017-03-28 | adenosine | Its name | ClinicalTrials.gov |
1 to 10 of 76
See all 76 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Cardiac Perforation | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Pulmonary Vein Stenosis | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Number of Subjects Who Need Repeat Ablations | 12 of 61 | 9 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Death | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Stroke | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: deaths from any cause | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Atrio-esophageal Fistula | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Freedom From Any Atrial Arrhythmias | 24 of 61 | 23 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: serious adverse events | 4 of 61 | 3 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenoscan vs Regadenson: serious adverse events | 0 of 48 | 0 of 48 | 96 | NCT01482169 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials58
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL477
GET https://conductscience.org/api/drugs/v1/CHEMBL477/diseases?page=2